Age-related disease is arguably the single greatest challenge for biomedicine in the 21st Century. Age is the largest single risk factor for a panoply of diseases, including cardiovascular dysfunction, cancer, type II diabetes, osteoporosis, and neurodegeneration. Postponing (or decreasing the rate of) aging would retard the course of multiple age-related diseases and therefore substantially increase average health-span. Our ability to develop rational approaches to preventing or intervening in aging depends crucially on a thorough understanding of the basic mechanisms that cause aging, as well as the etiology of specific agerelated diseases. We believe that it is especially in this area of biomedicine where an interdisciplinary approach will accelerate discoveries and provide rational avenues for therapeutic intervention. In the long term this will lead to the establishment of a comprehensive new discipline, that of """"""""Geroscience."""""""" Despite having identified 100s of genes that determine lifespan in simple organisms, we have no true understanding of how these genes are impacting on aging and disease. This is in part that most studies are carried in isolation by either looking at the basic biology of aging or separately at the impact of these identified genes on disease. In this proposal, which is directly relevant to Specfic Aim 1 of the U54, Specific Aim 1. To establish an interdisciplinary research program on the aging-disease relationship with a focus on neurodegeneration and cancer, we will address across three neurodegenerative disease models, Huntington's disease-Dr. Ellerby (Component 7), Dr. Hughes (Component 6), Dr. Nicholls and Gibson (Component 11), Parkinson's disease-Dr. Andersen (Component 9) and Alzheimer's disease-Dr. Bredesen (Component 1), and the model organism C. elegans-Dr. Kapahi (Component 2)- the role of histone deacetylase (HDACs) in neurodegeneration and aging. This represents a significant area as researchers have made a series of important discoveries in recent years on neurodegenerative disease and in aging that these enzymes (HDACs) play a major in role in neurodegeneration or aging. However, researchers have not yet dissected out in mammalian systems which family members are critical to target to prevent neurodegeneration and aging. A central theme of these projects is the notion that genes that are known to modulate aging are key factors in determining disease. Drugs that target the maintenance functions of these regulators or enhance their function will be important targets for proposed interventions. Our hypothesis is that compromised acetylation homoeostasis is directed coupled to neurodegeneration and identification of particular HDACs family members involved in this process will identify therapeutic targets critical to neurodegeneration and aging.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Linked Research project Grant (RL1)
Project #
5RL1NS062413-04
Application #
7878516
Study Section
Special Emphasis Panel (ZRR1-SRC (99))
Program Officer
Sutherland, Margaret L
Project Start
2007-09-30
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
4
Fiscal Year
2010
Total Cost
$475,565
Indirect Cost
Name
Buck Institute for Age Research
Department
Type
DUNS #
786502351
City
Novato
State
CA
Country
United States
Zip Code
94945
Tracy, Tara E; Sohn, Peter Dongmin; Minami, S Sakura et al. (2016) Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron 90:245-60
Guyenet, Stephan J; Mookerjee, Shona S; Lin, Amy et al. (2015) Proteolytic cleavage of ataxin-7 promotes SCA7 retinal degeneration and neurological dysfunction. Hum Mol Genet 24:3908-17
Min, Sang-Won; Chen, Xu; Tracy, Tara E et al. (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21:1154-62
Duncan, Carlotta E; An, Mahru C; Papanikolaou, Theodora et al. (2013) Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Mol Neurodegener 8:42
Cong, Xin; Held, Jason M; DeGiacomo, Francesco et al. (2011) Mass spectrometric identification of novel lysine acetylation sites in huntingtin. Mol Cell Proteomics 10:M111.009829
Duncan, Carlotta; Papanikolaou, Theodora; Ellerby, Lisa M (2010) Autophagy: polyQ toxic fragment turnover. Autophagy 6:312-4
Miller, John P; Holcomb, Jennifer; Al-Ramahi, Ismael et al. (2010) Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67:199-212
Mookerjee, Shona; Papanikolaou, Theodora; Guyenet, Stephan J et al. (2009) Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. J Neurosci 29:15134-44